OpenAI’s “GPT for life sciences” is getting the hype cycle treatment. But the real question isn’t whether the model can sound smart about biology—it’s what it actually changes in the drug development machine.
Because in pharma, the bottleneck rarely li…

Most biosimilar strategies fail for one reason: they show up too late.
In biosimilars, timing isn’t a detail—it’s the business model. Yet too many teams still build their go-to-market plans around a familiar assumption: patent expiry is a date on a cal…

Europe’s drug patent clock is ticking—and most people misunderstand where it actually stops.
In pharma, “patent protection” sounds like a single, clean deadline. In reality, it’s a layered timeline—one that can extend, fracture, or collapse depending o…

Drug discovery timelines are getting longer—and the cost of waiting is rising. The industry has tried to “speed up” with more headcount, more vendors, and more data. But the bottleneck often isn’t effort. It’s coordination: turning messy scientific inp…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar Problem. Here’s How Commercial Market Access Teams Can Stop Getting Blindsided.
If you work in commercial market access, you’ve seen it: the sudden scramble when a brand’s exclusivity window s…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be a moat. File early, win the patent fight, capture exclusivity, and monetize the runway. But in today’s branded-drug landscape, th…

The clock is ticking—and “generic” isn’t one size fits all.
In the race to launch true generics, the biggest risk isn’t manufacturing or pricing. It’s timing. And timing in pharma isn’t governed by a single date on a calendar—it’s governed by a patch…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

Generic competition doesn’t just change prices—it redraws the map of who gets paid, who gets blocked, and who ultimately serves patients.
That’s the real story behind Paragraph IV challenges and pay-for-delay settlements—the “patent war” that often p…

Consumers don’t just pay for pills. They pay for certainty.
That’s the unglamorous truth behind why many people—often without realizing it—end up paying a “trust premium” for branded generics. The term sounds contradictory, but the economics are straig…